Thomas Dick

Bedaquiline Eliminates Bactericidal Activity of β-Lactams against Mycobacterium abscessus.

Repositioning rifamycins for Mycobacterium abscessus lung disease.

Editorial: NTM-The New Uber-Bugs.

TBAJ-876 Retains Bedaquiline's Activity against Subunits c and ε of F-ATP Synthase.

Identification of New MmpL3 Inhibitors by Untargeted and Targeted Mutant Screens Defines MmpL3 Domains with Differential Resistance.

Phase variation in produces transiently heritable drug tolerance.

Pharmacological and Molecular Mechanisms Behind the Sterilizing Activity of Pyrazinamide.

TBAJ-876 Displays Bedaquiline-Like Mycobactericidal Potency without Retaining the Parental Drug's Uncoupler Activity.

Disrupting coupling within mycobacterial F-ATP synthases subunit ε causes dysregulated energy production and cell wall biosynthesis.

Targeted protein degradation in antibacterial drug discovery?

Unique structural and mechanistic properties of mycobacterial F-ATP synthases: Implications for drug design.

Overexpression, purification, enzymatic and microscopic characterization of recombinant mycobacterial F-ATP synthase.

Rifabutin Is Active against Mycobacterium abscessus in Mice.

Re-Understanding the Mechanisms of Action of the Anti-Mycobacterial Drug Bedaquiline.

TBAJ-876, a 3,5-Dialkoxypyridine Analogue of Bedaquiline, Is Active against Mycobacterium abscessus.

Rifabutin Suppresses Inducible Clarithromycin Resistance in by Blocking Induction of and .

Reply to Vargas and Farhat: mutants in human tuberculosis.

Antituberculosis Activity of the Antimalaria Cytochrome Oxidase Inhibitor SCR0911.

Rifabutin: A Repurposing Candidate for Lung Disease.

Extreme Drug Tolerance of "Persisters".

Pyrazinamide triggers degradation of its target aspartate decarboxylase.

Discovery of a Novel Mycobacterial F-ATP Synthase Inhibitor and its Potency in Combination with Diarylquinolines.

Potency Increase of Spiroketal Analogs of Membrane Inserting Indolyl Mannich Base Antimycobacterials Is Due to Acquisition of MmpL3 Inhibition.

A systematic assessment of mycobacterial F -ATPase subunit ε's role in latent ATPase hydrolysis.

Resistance against Membrane-Inserting MmpL3 Inhibitor through Upregulation of MmpL5 in Mycobacterium tuberculosis.

Single Cell Analysis of Drug Susceptibility of During Macrophage Infection.

Indole Propionic Acid, an Unusual Antibiotic Produced by the Gut Microbiota, With Anti-inflammatory and Antioxidant Properties.

A Leucyl-tRNA Synthetase Inhibitor with Broad-Spectrum Anti-Mycobacterial Activity.

PanD Structure-Function Analysis and Identification of a Potent Pyrazinoic Acid-Derived Enzyme Inhibitor.

Piperidine-4-Carboxamides Target DNA Gyrase in Mycobacterium abscessus.

Amide-Amine Replacement in Indole-2-carboxamides Yields Potent Mycobactericidal Agents with Improved Water Solubility.

Reinvestigation of the structure-activity relationships of isoniazid.

A Ginger Root or Plum Model for the Tuberculosis "Granuloma"?

Potency boost of a dihydrofolate reductase inhibitor by multienzyme FH-dependent reduction.

Blocking Bacterial Naphthohydroquinone Oxidation and ADP-Ribosylation Improves Activity of Rifamycins against Mycobacterium abscessus.

Epetraborole Is Active against Mycobacterium abscessus.

A Mycobacterium tuberculosis NBTI DNA Gyrase Inhibitor Is Active against Mycobacterium abscessus.

Critical discussion on drug efflux in Mycobacterium tuberculosis.

Functionalized Dioxonaphthoimidazoliums: A Redox Cycling Chemotype with Potent Bactericidal Activities against .

Cyclohexyl-griselimycin Is Active against Mycobacterium abscessus in Mice.

Resistance against DNA Gyrase Inhibitor SPR719 in Mycobacterium avium and Mycobacterium abscessus.

A Rabbit Model to Study Antibiotic Penetration at the Site of Infection for Nontuberculous Mycobacterial Lung Disease: Macrolide Case Study.

Mutational Analysis of Mycobacterial F-ATP Synthase Subunit δ Leads to a Potent δ Enzyme Inhibitor.

Structure-Activity Relationship of Anti- Piperidine-4-carboxamides, a New Class of NBTI DNA Gyrase Inhibitors.

Anti-Mycobacterium abscessus Activity of Tuberculosis F-ATP Synthase Inhibitor GaMF1.

Drug development challenges in nontuberculous mycobacterial lung disease: TB to the rescue.

Atomic solution structure of Mycobacterium abscessus F-ATP synthase subunit ε and identification of Ep1MabF1 as a targeted inhibitor.

Structural and Mechanistic Insights into Aspartate Decarboxylase PanD and a Pyrazinoic Acid-Derived Inhibitor.

Activity of Tricyclic Pyrrolopyrimidine Gyrase B Inhibitor against Mycobacterium abscessus.

Strongly Bactericidal All-Oral β-Lactam Combinations for the Treatment of Mycobacterium abscessus Lung Disease.

Redesign of Rifamycin Antibiotics to Overcome ADP-Ribosylation-Mediated Resistance.

Structure activity relationship of pyrazinoic acid analogs as potential antimycobacterial agents.

Why Matter Matters: Fast-Tracking Drug Discovery.

Mycobacterium tuberculosis DprE1 Inhibitor OPC-167832 Is Active against Mycobacterium abscessus .

Profiling of the Synthetic RNA Polymerase Inhibitor MMV688845 against Mycobacterium abscessus.

Redox Cycling Dioxonaphthoimidazoliums Disrupt Iron Homeostasis in Mycobacterium bovis Bacillus Calmette-Guérin.

Expanding the knowledge around antitubercular 5-(2-aminothiazol-4-yl)isoxazole-3-carboxamides: Hit-to-lead optimization and release of a novel antitubercular chemotype via scaffold derivatization.

Structural Elements Involved in ATP Hydrolysis Inhibition and ATP Synthesis of Tuberculosis and Nontuberculous Mycobacterial F-ATP Synthase Decipher New Targets for Inhibitors.

Alkyltriphenylphosphonium turns naphthoquinoneimidazoles into potent membrane depolarizers against .

Activity of Oral Tebipenem-Avibactam in a Mouse Model of Mycobacterium abscessus Lung Infection.

Synthesis and Testing of Analogs of the Tuberculosis Drug Candidate SQ109 against Bacteria and Protozoa: Identification of Lead Compounds against and Malaria Parasites.

Side-by-Side Profiling of Oxazolidinones to Estimate the Therapeutic Window against Mycobacterial Infections.

Synthesis and Characterization of Phenylalanine Amides Active against and Other Mycobacteria.

PROTAC antibiotics: the time is now.

Characterization of Resistance to Linezolid in Mycobacterium abscessus.

ADP-ribosylation-resistant rifabutin analogs show improved bactericidal activity against drug-tolerant in caseum surrogate.

Blocking ADP-ribosylation expands the anti-mycobacterial spectrum of rifamycins.

GaMF1.39's antibiotic efficacy and its enhanced antitubercular activity in combination with clofazimine, Telacebec, ND-011992, or TBAJ-876.

Pharmacological validation of dihydrofolate reductase as a drug target in .

Oral β-Lactam Pairs for the Treatment of Mycobacterium avium Complex Pulmonary Disease.

High efficacy of the F-ATP synthase inhibitor TBAJ-5307 against nontuberculous mycobacteria in vitro and in vivo.

Synthesis and in vitro Metabolic Stability of Sterically Shielded Antimycobacterial Phenylalanine Amides.

Therapeutic developments for tuberculosis and nontuberculous mycobacterial lung disease.

A pairwise approach to revitalize β-lactams for the treatment of TB.

Rifampicin has no role in treatment of complex pulmonary disease and bactericidal sterilising drugs are needed: a viewpoint.

Preclinical murine models for the testing of antimicrobials against Mycobacterium abscessus pulmonary infections: Current practices and recommendations.

Broad-Spectrum In Vitro Activity of α-Aroyl--Aryl-Phenylalanine Amides against Non-Tuberculous Mycobacteria and Comparative Analysis of RNA Polymerases.

Splenic marginal zone B cells restrict Mycobacterium tuberculosis infection by shaping the cytokine pattern and cell-mediated immunity.

Toward better cures for lung disease.

Multidrug tolerance conferred by loss-of-function mutations in anti-sigma factor RshA of .

Durlobactam to boost the clinical utility of standard of care β-lactams against lung disease.

Toward a Bactericidal Oral Drug Combination for the Treatment of Lung Disease.